46 results
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
2 Nov 21
Current report (foreign)
4:16pm
arrangements for any of our product candidates.
Research and Development (“R&D”) Expenses
Research and development expenses include:
employee … future operating profits. As a company that carries out extensive research and development activities, we benefit from the U.K. R&D small or medium-sized
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
7 Sep 23
Current report (foreign)
7:37am
product candidates.
Research and Development (“R&D”) Expenses
Research and development expenses include:
employee-related expenses, such as salaries … and development activities, we benefit from the U.K. R&D small or medium-sized enterprise tax credit regime and are able to surrender some of our trading
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
2 Nov 22
Current report (foreign)
4:17pm
arrangements for any of our product candidates.
Research and Development (“R&D”) Expenses
Research and development expenses include:
employee … benefit from the U.K. R&D small or medium-sized enterprise tax credit regime and are able to surrender some of our trading losses that arise from our
6-K
MREO
Mereo Biopharma Group Plc
14 Mar 22
Current report (foreign)
10:05am
On March 14, 2022, Mereo BioPharma Group plc (the “Company”) is hosting a virtual research and development (R&D) day to review the Company’s alvelestat … of the Company’s management team.
Highlights from the virtual R&D Day include:
An update on the ASTRAEUS 12-week Phase 2 trial for alvelestat in AATD
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
16 Nov 20
Current report (foreign)
7:27am
Exhibit 99.1
Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020
London and Redwood City, Calif., November 16, 2020 - Mereo … , today announced it will host a virtual R&D day on Tuesday, November 24, to review the Company’s key pipeline programs including etigilimab (Anti-TIGIT
6-K
EX-99.1
mwj18pb3m4j2v5
31 Mar 21
Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights
5:13pm
6-K
EX-99.1
7svxxhaovz43fgx zqko
31 Mar 22
Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights
4:18pm
6-K
EX-99.3
cgdjet7w
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
h12py5169glq
19 Oct 20
Current report (foreign)
8:10am
6-K
3sir mm81rb7zcztx
29 Apr 19
Current report (foreign)
12:09pm
6-K
3h4 1839b
16 Jun 20
Current report (foreign)
4:13pm
425
y43mfeyb9hrp01rdh
7 Jan 19
Business combination disclosure
11:50am
425
k6cy7p435uinp56v3n85
15 Feb 19
Business combination disclosure
6:50am
6-K
x3ler
17 Sep 19
Current report (foreign)
8:06am
6-K
EX-99.1
t0lj67e7lnnpx
17 Oct 22
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of
7:16am
6-K
EX-99.1
hltbcyv1wkb5d78
20 Sep 21
Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors
8:20am
8-K
EX-99.1
yhrf9bm6 m3gpk8
15 May 24
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
425
kzel 95q9f
12 Feb 19
Business combination disclosure
12:00am
425
b4400puww0r
11 Dec 18
Business combination disclosure
1:16pm
10-K
z6a7e7c
27 Mar 24
Annual report
5:20pm